FRIDAY, Nov. 5 (HealthDay News) -- The combination drug
Kombiglyze (saxagliptin, metformin XR) has been approved by the
U.S. Food and Drug Administration to help control blood sugar in
adults with type 2 diabetes, makers AstraZeneca and Bristol-Myers
Squibb said Friday.
Kombiglyze XR combines a DPP-4 inhibitor called saxagliptin
(brand name: Onglyza) with a popular biguanide called metformin XR,
the companies said in a news release.
The combination drug has a boxed label warning for lactic
acidosis, a rare but serious complication caused by accumulation of
metformin, the drug makers said.
Approval of the combined active ingredients in Kombiglyze XR was
based on clinical studies involving more than 2,000 adults with
type 2 diabetes. The most common adverse reactions were diarrhea
To learn more about type 2 diabetes, visit the
American Diabetes Association.